Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease

• Status: Completed
• Trial end date: 2017-12-19
• Target enrollment: 0
• Participant gender: All

Summary

FOS improve gut colonization by Faecalibacterium prausnitzii in patients with Crohn's disease

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute
• Collaborator: AbbVie
• Treatments: Adalimumab

Criteria

Inclusion Criteria:

• Patients between 18 and 65 years old

• Crohn's disease patients

• Inflammatory activity confirmed by imaging techniques (colonoscopy or magnetic resonance imaging (MRI))

• Refractory inflammatory luminal disease (with or without perianal involvement) at any level of the gastrointestinal tract requiring therapy with adalimumab,according to standard clinical practice.

• Stable maintenance of any other medication (corticosteroids and / or immunosuppressants and/or 5-aminosalicylic acid (5-ASA)) for the past 4 weeks

• Screening tests required for a safe administration of anti tumour necrosis factor (anti-TNF) antibodies will be performed according to standard clinical practice

Exclusion Criteria:

• Subjects consuming prebiotic supplements (inulin, FOS, galactooligosaccharides (GOS)) in their regular diet.

• Antibiotic use within the past 2 months

• Previous anti-TNF therapy.